The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019
Open accessAbstract
PURPOSE: Germline testing (GT) is a central feature of prostate cancer (PCA) treatment, management, and hereditary cancer assessment. Critical needs include optimized multigene testing strategies that incorporate evolving genetic data, consistency in GT indications and management, and alternate genetic evaluation models that address the rising demand for genetic services. METHODS: A multidisciplinary consensus conference that included experts, stakeholders, and national organization leaders was convened in response to current practice challenges and to develop a genetic implementation framework. Evidence review informed questions using the modified Delphi model. The final framework included criteria with strong (> 75%) agreement (Recommend) or moderate (50% to 74%) agreement (Consider). RESULTS: Large germline panels and somatic testing were recommended for metastatic PCA. Reflex testing—initial testing of priority genes followed by expanded testing—was suggested for multiple scenarios. Metastatic disease or family history suggestive of hereditary PCA was recommended for GT. Additional family history and pathologic criteria garnered moderate consensus. Priority genes to test for metastatic disease treatment included BRCA2, BRCA1, and mismatch repair genes, with broader testing, such as ATM, for clinical trial eligibility. BRCA2 was recommended for active surveillance discussions. Screening starting at age 40 years or 10 years before the youngest PCA diagnosis in a family was recommended for BRCA2 carriers, with consideration in HOXB13, BRCA1, ATM, and mismatch repair carriers. Collaborative (point-of-care) evaluation models between health care and genetic providers was endorsed to address the genetic counseling shortage. The genetic evaluation framework included optimal pretest informed consent, post-test discussion, cascade testing, and technology-based approaches. CONCLUSION: This multidisciplinary, consensus-driven PCA genetic implementation framework provides novel guidance to clinicians and patients tailored to the precision era. Multiple research, education, and policy needs remain of importance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
Self-citationDNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506859 · Cited by 2,185
Self-citationInherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
Pritchard, C. C., Mateo, J., Walsh, M. F., De Sarkar, N., Abida, W., Beltran, H., Garofalo, A., Gulati, R., Carreira, S., Eeles, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603144 · Cited by 1,680
Self-citationCancer Risks in BRCA2 Mutation Carriers
Breast Cancer Linkage Consortium, T. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.15.1310 · Cited by 1,527
Daly, M. B., Pal, T., Berry, M. P., Buys, S. S., Dickson, P., Domchek, S. M., Elkhanany, A., Friedman, S., Goggins, M., Hutton, M. L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0001 · Cited by 1,112
Self-citationCancer Incidence in BRCA1 Mutation Carriers
Thompson, D. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.18.1358 · Cited by 1,096
Robson, M. E., Bradbury, A. R., Arun, B., Domchek, S. M., Ford, J. M., Hampel, H. L., Lipkin, S. M., Syngal, S., Wollins, D. S., & Lindor, N. M. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.0996 · Cited by 934
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci
Study, T. P., Schumacher, F. R., (APCB), A. P. C. B., Study, T. I., Canary PASS Investigators, Breast and Prostate Cancer Cohort Consortium (BPC3), The PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, (CAPS), C. O. T. P. I. S., Prostate Cancer Genome-wide Association Study of Uncommon Susceptibility Loci (PEGASUS), The Genetic Associations and Mechanisms in Oncology (GAME-ON)/Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE) Consortium, et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0142-8 · Cited by 902
Self-citationMohler, J., Bahnson, R. R., Boston, B., Busby, J. E., D'Amico, A., Eastham, J. A., Enke, C. A., George, D., Horwitz, E. M., Huben, R. P., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0012 · Cited by 897
Self-citationCastro, E., Goh, C., Olmos, D., Saunders, E., Leongamornlert, D., Tymrakiewicz, M., Mahmud, N., Dadaev, T., Govindasami, K., Guy, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.1882 · Cited by 850
Dominguez-Valentin, M., Sampson, J. R., Seppälä, T. T., ten Broeke, S. W., Plazzer, J.-P., Nakken, S., Engel, C., Aretz, S., Jenkins, M. A., Sunde, L., et al. (2020) · Genetics in Medicine · doi:10.1038/s41436-019-0596-9 · Cited by 662
Goggins, M., Overbeek, K. A., Brand, R., Syngal, S., Del Chiaro, M., Bartsch, D. K., Bassi, C., Carrato, A., Farrell, J., Fishman, E. K., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-319352 · Cited by 659
Germline Mutations in HOXB13 and Prostate-Cancer Risk
Ewing, C. M., Ray, A. M., Lange, E. M., Zuhlke, K. A., Robbins, C. M., Tembe, W. D., Wiley, K. E., Isaacs, S. D., Johng, D., Wang, Y., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110000 · Cited by 658
Self-citationHampel, H., Bennett, R. L., Buchanan, A., Pearlman, R., & Wiesner, G. L. (2015) · Genetics in Medicine · doi:10.1038/gim.2014.147 · Cited by 587
Integrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.06.053 · Cited by 571
Self-citationCancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian
Mersch, J., Jackson, M. A., Park, M., Nebgen, D., Peterson, S. K., Singletary, C., Arun, B. K., & Litton, J. K. (2015) · Cancer · doi:10.1002/cncr.29041 · Cited by 511
Mai, P. L., Best, A. F., Peters, J. A., DeCastro, R. M., Khincha, P. P., Loud, J. T., Bremer, R. C., Rosenberg, P. S., & Savage, S. A. (2016) · Cancer · doi:10.1002/cncr.30248 · Cited by 486
A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer
The Breast and Prostate Cancer Cohort Consortium (BPC3), Al Olama, A. A., The PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, The COGS (Collaborative Oncological Gene-environment Study) Consortium, The GAME-ON/ELLIPSE Consortium, Kote-Jarai, Z., Berndt, S. I., Conti, D. V., Schumacher, F., Han, Y., et al. (2014) · Nature Genetics · doi:10.1038/ng.3094 · Cited by 455
Self-citationCastro, E., Romero-Laorden, N., del Pozo, A., Lozano, R., Medina, A., Puente, J., Piulats, J. M., Lorente, D., Saez, M. I., Morales-Barrera, R., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00358 · Cited by 377
Self-citationThe Global State of the Genetic Counseling Profession
Abacan, M., Alsubaie, L., Barlow-Stewart, K., Caanen, B., Cordier, C., Courtney, E., Davoine, E., Edwards, J., Elackatt, N. J., Gardiner, K., et al. (2019) · European Journal of Human Genetics · doi:10.1038/s41431-018-0252-x · Cited by 371
Castro, E., Goh, C., Leongamornlert, D., Saunders, E., Tymrakiewicz, M., Dadaev, T., Govindasami, K., Guy, M., Ellis, S., Frost, D., et al. (2015) · European Urology · doi:10.1016/j.eururo.2014.10.022 · Cited by 368
Nicolosi, P., Ledet, E., Yang, S., Michalski, S., Freschi, B., O’Leary, E., Esplin, E. D., Nussbaum, R. L., & Sartor, O. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.6760 · Cited by 365
Self-citationNa, R., Zheng, S. L., Han, M., Yu, H., Jiang, D., Shah, S., Ewing, C. M., Zhang, L., Novakovic, K., Petkewicz, J., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.11.033 · Cited by 343
Self-citationRiley, B. D., Culver, J. O., Skrzynia, C., Senter, L. A., Peters, J. A., Costalas, J. W., Callif‐Daley, F., Grumet, S. C., Hunt, K. S., Nagy, R. S., et al. (2012) · Journal of Genetic Counseling · doi:10.1007/s10897-011-9462-x · Cited by 328
Prostate cancer in young men: an important clinical entity
Salinas, C. A., Tsodikov, A., Ishak-Howard, M., & Cooney, K. A. (2014) · Nature Reviews Urology · doi:10.1038/nrurol.2014.91 · Cited by 304
Self-citationGermline BRCA Mutations Denote a Clinicopathologic Subset of Prostate Cancer
Gallagher, D. J., Gaudet, M. M., Pal, P., Kirchhoff, T., Balistreri, L., Vora, K., Bhatia, J., Stadler, Z., Fine, S. W., Reuter, V., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2871 · Cited by 301
Self-citationPomerantz, M. M., Spisák, S., Jia, L., Cronin, A. M., Csabai, I., Ledet, E., Sartor, A. O., Rainville, I., O'Connor, E. P., Herbert, Z. T., et al. (2017) · Cancer · doi:10.1002/cncr.30808 · Cited by 257
Self-citationSchwartz, M. D., Valdimarsdottir, H. B., Peshkin, B. N., Mandelblatt, J., Nusbaum, R., Huang, A.-T., Chang, Y., Graves, K., Isaacs, C., Wood, M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.3226 · Cited by 253
Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study
Nyberg, T., Frost, D., Barrowdale, D., Evans, D. G., Bancroft, E., Adlard, J., Ahmed, M., Barwell, J., Brady, A. F., Brewer, C., et al. (2020) · European Urology · doi:10.1016/j.eururo.2019.08.025 · Cited by 248
Page, E. C., Bancroft, E. K., Brook, M. N., Assel, M., Hassan Al Battat, M., Thomas, S., Taylor, N., Chamberlain, A., Pope, J., Raghallaigh, H. N., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.08.019 · Cited by 247
Self-citationProstate Cancer Progression and Survival in BRCA2 Mutation Carriers
Tryggvadottir, L., Vidarsdottir, L., Thorgeirsson, T., Jonasson, J. G., Olafsdottir, E. J., Olafsdottir, G. H., Rafnar, T., Thorlacius, S., Jonsson, E., Eyfjord, J. E., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm005 · Cited by 231
Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair–deficient Prostate Cancer
Annala, M., Struss, W. J., Warner, E. W., Beja, K., Vandekerkhove, G., Wong, A., Khalaf, D., Seppälä, I.-L., So, A., Lo, G., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.02.023 · Cited by 218
Seibert, T. M., Fan, C. C., Wang, Y., Zuber, V., Karunamuni, R., Parsons, J. K., Eeles, R. A., Easton, D. F., Kote-Jarai, Z., Al Olama, A. A., et al. (2018) · BMJ · doi:10.1136/bmj.j5757 · Cited by 215
Self-citationCarter, H. B., Helfand, B., Mamawala, M., Wu, Y., Landis, P., Yu, H., Wiley, K., Na, R., Shi, Z., Petkewicz, J., et al. (2019) · European Urology · doi:10.1016/j.eururo.2018.09.021 · Cited by 215
Self-citationPALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS
Southey, M. C., Goldgar, D. E., Winqvist, R., Pylkäs, K., Couch, F., Tischkowitz, M., Foulkes, W. D., Dennis, J., Michailidou, K., van Rensburg, E. J., et al. (2016) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2016-103839 · Cited by 213
Self-citationStoll, K., Kubendran, S., & Cohen, S. A. (2018) · American Journal of Medical Genetics Part C: Seminars in Medical Genetics · doi:10.1002/ajmg.c.31602 · Cited by 211
International Consortium for Prostate Cancer Genetics, Xu, J., Lange, E. M., Lu, L., Zheng, S. L., Wang, Z., Thibodeau, S. N., Cannon-Albright, L. A., Teerlink, C. C., Camp, N. J., et al. (2013) · Human Genetics · doi:10.1007/s00439-012-1229-4 · Cited by 201
Self-citationGiri, V. N., Knudsen, K. E., Kelly, W. K., Abida, W., Andriole, G. L., Bangma, C. H., Bekelman, J. E., Benson, M. C., Blanco, A., Burnett, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.1173 · Cited by 191
Self-citationProstate Cancer Early Detection
Kawachi, M. H., Bahnson, R. R., Barry, M., Busby, J. E., Carroll, P. R., Carter, H. B., Catalona, W. J., Cookson, M. S., Epstein, J. I., Etzioni, R. B., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0016 · Cited by 189
Self-citationAmadou, A., Waddington Achatz, M. I., & Hainaut, P. (2018) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000423 · Cited by 187
Antonarakis, E. S., Lu, C., Luber, B., Liang, C., Wang, H., Chen, Y., Silberstein, J. L., Piana, D., Lai, Z., Chen, Y., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.01.035 · Cited by 179
Self-citationBRCA Mutations and Risk of Prostate Cancer in Ashkenazi Jews
Kirchhoff, T., Kauff, N. D., Mitra, N., Nafa, K., Huang, H., Palmer, C., Gulati, T., Wadsworth, E., Donat, S., Robson, M. E., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0604 · Cited by 165
Telegenetics: a systematic review of telemedicine in genetics services
Hilgart, J. S., Hayward, J. A., Coles, B., & Iredale, R. (2012) · Genetics in Medicine · doi:10.1038/gim.2012.40 · Cited by 165
NBS1 Is a Prostate Cancer Susceptibility Gene
Cybulski, C., Górski, B., Dębniak, T., Gliniewicz, B., Mierzejewski, M., Masojć, B., Jakubowska, A., Matyjasik, J., Złowocka, E., Sikorski, A., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2502 · Cited by 164
Fritsche, L. G., Gruber, S. B., Wu, Z., Schmidt, E. M., Zawistowski, M., Moser, S. E., Blanc, V. M., Brummett, C. M., Kheterpal, S., Abecasis, G. R., et al. (2018) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2018.04.001 · Cited by 162
A Review of Prostate Cancer Genome-Wide Association Studies (GWAS)
Benafif, S., Kote-Jarai, Z., & Eeles, R. A. (2018) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-16-1046 · Cited by 162
Marshall, C. H., Sokolova, A. O., McNatty, A. L., Cheng, H. H., Eisenberger, M. A., Bryce, A. H., Schweizer, M. T., & Antonarakis, E. S. (2019) · European Urology · doi:10.1016/j.eururo.2019.02.002 · Cited by 162
Self-citationGene Panel Testing for Inherited Cancer Risk
Hall, M. J., Forman, A. D., Pilarski, R., Wiesner, G. L., & Giri, V. N. (2014) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2014.0128 · Cited by 159
Self-citationGermline and Somatic Mutations in Prostate Cancer for the Clinician
Cheng, H. H., Sokolova, A. O., Schaeffer, E. M., Small, E. J., & Higano, C. S. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.7307 · Cited by 148
Self-citationAssociations of High-Grade Prostate Cancer withBRCA1andBRCA2Founder Mutations
Agalliu, I., Gern, R. W., Leanza, S. M., & Burk, R. D. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1822 · Cited by 147
Velho, P. I., Silberstein, J. L., Markowski, M. C., Luo, J., Lotan, T. L., Isaacs, W. B., & Antonarakis, E. S. (2018) · The Prostate · doi:10.1002/pros.23484 · Cited by 141
Self-citationRisk of Prostate Cancer in Lynch Syndrome: A Systematic Review and Meta-analysis
Ryan, S., Jenkins, M. A., & Win, A. K. (2014) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-13-1165 · Cited by 140
Telegenetics: a systematic review of telemedicine in genetics services.
Hilgart, J., Hayward, J. A., Coles, B., & Iredale, R. (2012) · PubMed · Cited by 130
Mateo, J., Cheng, H. H., Beltran, H., Dolling, D. I., Xu, W., Pritchard, C. C., Mossop, H., Rescigno, P., Pérez-López, R., Sailer, V., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.01.010 · Cited by 127
Self-citationAlternate Service Delivery Models in Cancer Genetic Counseling: A Mini-Review
Buchanan, A. H., Rahm, A. K., & Williams, J. L. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00120 · Cited by 125
Self-citationThorne, H., Willems, A. J., Niedermayr, E., Hoh, I., Li, J., Clouston, D. R., Mitchell, G., Fox, S. B., Hopper, J. L., & Bolton, D. M. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0397 · Cited by 111
Giri, V. N., Hegarty, S., Hyatt, C., O’Leary, E., Garcia, J., Knudsen, K. E., Kelly, W. K., & Gomella, L. G. (2018) · The Prostate · doi:10.1002/pros.23739 · Cited by 109
Self-citationGermline Pathogenic Variants in 7636 Japanese Patients With Prostate Cancer and 12 366 Controls
Momozawa, Y., Iwasaki, Y., Hirata, M., Liu, X., Kamatani, Y., Takahashi, A., Sugano, K., Yoshida, T., Murakami, Y., Matsuda, K., et al. (2019) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djz124 · Cited by 105
A systematic review of the prevalence of DNA damage response gene mutations in prostate cancer
Lang, S., Swift, S. L., White, H., Misso, K., Kleijnen, J., & Quek, R. G. W. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4842 · Cited by 103
Assessing Genetic Risks: Implications for Health and Social Policy
Read, A. (1994) · BMJ · doi:10.1136/bmj.309.6966.1450 · Cited by 100
Schweizer, M. T., Antonarakis, E. S., Bismar, T. A., Guedes, L. B., Cheng, H. H., Tretiakova, M., Vakar‐Lopez, F., Klemfuss, N. M., Konnick, E. Q., Mostaghel, E. A., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00327 · Cited by 98
Self-citationCoelho, J. J., Arnold, A. G., Nayler, J., Tischkowitz, M. D., & MacKay, J. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.06.020 · Cited by 97
ATM polymorphisms as risk factors for prostate cancer development
Angèle, S., Falconer, A., Edwards, S. M., Dörk, T., Bremer, M., Moullan, N., Chapot, B., Muir, K. R., Houlston, R. S., Norman, A. R., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602007 · Cited by 97
Differences in TP53 Mutation Carrier Phenotypes Emerge From Panel-Based Testing
Rana, H. Q., Gelman, R. S., LaDuca, H., McFarland, R. E., Dalton, E., Thompson, J. D., Speare, V., Dolinsky, J. S., Chao, E., & Garber, J. E. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy001 · Cited by 97
Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry
Conti, D. V., Wang, K., Sheng, X., Bensen, J. T., Hazelett, D. J., Cook, M. B., Ingles, S. A., Kittles, R. A., Strom, S. S., Rybicki, B. A., et al. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx084 · Cited by 89
Self-citationGiri, V. N., Obeid, E. I., Gross, L., Bealin, L., Hyatt, C., Hegarty, S., Montgomery, S. V., Forman, A. D., Bingler, R., Kelly, W. K., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.16.00039 · Cited by 73
Self-citationA comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer
Wu, Y., Yu, H., Zheng, S. L., Na, R., Mamawala, M. K., Landis, T., Wiley, K. E., Petkewicz, J., Shah, S., Shi, Z., et al. (2018) · The Prostate · doi:10.1002/pros.23505 · Cited by 73
Self-citationLeongamornlert, D. A., Saunders, E. J., Wakerell, S., Whitmore, I., Dadaev, T., Cieza-Borrella, C., Benafif, S., Brook, M. N., Donovan, J., Hamdy, F. C., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.01.050 · Cited by 67
Paller, C. J., Antonarakis, E. S., Beer, T. M., Borno, H. T., Carlo, M. I., George, D. J., Graff, J. N., Gupta, S., Heath, E. I., Higano, C. S., et al. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.04.013 · Cited by 67
Self-citationEthnic disparities among men with prostate cancer undergoing germline testing
Kwon, D. H.-M., Borno, H. T., Cheng, H. H., Zhou, A. Y., & Small, E. J. (2019) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2019.09.010 · Cited by 64
Self-citationAbida, W. M., Bryce, A. H., Vogelzang, N. J., Amato, R. J., Percent, I. J., Shapiro, J., McDermott, R., Hussain, A., Patnaik, A., Petrylak, D. P., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy284.002 · Cited by 54
Self-citationGiri, V. N., Hyatt, C., & Gomella, L. G. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02181 · Cited by 42
Self-citationATM missense variant P1054R predisposes to prostate cancer
Meyer, A. A., Wilhelm, B., Dörk, T., Bremer, M., Baumann, R., Karstens, J. H., & Machtens, S. A. (2007) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2007.04.029 · Cited by 41
Carlo, M. I., Giri, V. N., Paller, C. J., Abida, W. M., Alumkal, J. J., Beer, T. M., Beltran, H., George, D. J., Heath, E. I., Higano, C. S., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00060 · Cited by 33
Self-citationInherited NBN Mutations and Prostate Cancer Risk and Survival
Rusak, B., Kluźniak, W., Wokołorczykv, D., Stempa, K., Kashyap, A., Gronwald, J., Huzarski, T., Dębniak, T., Jakubowska, A., Masojć, B., et al. (2018) · Cancer Research and Treatment · doi:10.4143/crt.2018.532 · Cited by 30
Chandrasekar, T., Gross, L., Gomella, L. G., Hegarty, S., Leong, J. Y., & Giri, V. N. (2019) · European Urology Oncology · doi:10.1016/j.euo.2019.06.010 · Cited by 19
Self-citation
Cited by
Rebello, R. J., Oing, C., Knudsen, K. E., Loeb, S., Johnson, D. C., Reiter, R. E., Gillessen, S., Van der Kwast, T., & Bristow, R. G. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00243-0 · Cited by 1,090
Self-citationNetto, G. J., Amin, M. B., Berney, D. M., Compérat, E. M., Gill, A. J., Hartmann, A., Menon, S., Raspollini, M. R., Rubin, M. A., Srigley, J. R., et al. (2022) · European Urology · doi:10.1016/j.eururo.2022.07.002 · Cited by 316
Epidemiology and genomics of prostate cancer in Asian men
Zhu, Y., Mo, M., Wei, Y., Wu, J., Pan, J., Freedland, S. J., Zheng, Y., & Ye, D. (2021) · Nature Reviews Urology · doi:10.1038/s41585-021-00442-8 · Cited by 287
Germline Testing in Patients With Breast Cancer: ASCO–Society of Surgical Oncology Guideline
Bedrosian, I., Somerfield, M. R., Achatz, M. I., Boughey, J. C., Curigliano, G., Friedman, S., Kohlmann, W. K., Kurian, A. W., Laronga, C., Lynce, F., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02225 · Cited by 216
Germline and somatic genomic testing for metastatic prostate cancer: ASCO guideline
Yu, E. Y., Rumble, R. B., Agarwal, N., Cheng, H. H., Eggener, S. E., Bitting, R. L., Beltran, H., Giri, V. N., Spratt, D., Mahal, B., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02608 · Cited by 64
Self-citation
Metadata
- Authors
- Giri, V. N., Knudsen, K. E., Kelly, W. K., Cheng, H. H., Cooney, K. A., Cookson, M. S., Dahut, W., Weissman, S., Soule, H. R., Petrylak, D. P., Dicker, A. P., AlDubayan, S. H., Toland, A. E., Pritchard, C. C., Pettaway, C. A., Daly, M. B., Mohler, J. L., Parsons, J. K., Carroll, P. R., Pilarski, R., Blanco, A., Woodson, A., Rahm, A., Taplin, M.-E., Polascik, T. J., Helfand, B. T., Hyatt, C., Morgans, A. K., Feng, F., Mullane, M., Powers, J., Concepcion, R., Lin, D. W., Wender, R., Mark, J. R., Costello, A., Burnett, A. L., Sartor, O., Isaacs, W. B., Xu, J., Weitzel, J., Andriole, G. L., Beltran, H., Briganti, A., Byrne, L., Calvaresi, A., Chandrasekar, T., Chen, D. Y. T., Den, R. B., Dobi, A., Crawford, E. D., Eastham, J., Eggener, S., Freedman, M. L., Garnick, M., Gomella, P. T., Handley, N., Hurwitz, M. D., Izes, J., Karnes, R. J., Lallas, C., Languino, L., Loeb, S., Lopez, A. M., Loughlin, K. R., Lu-Yao, G., Malkowicz, S. B., Mann, M., Mille, P., Miner, M. M., Morgan, T., Moreno, J., Mucci, L., Myers, R. E., Nielsen, S. M., O’Neil, B., Pinover, W., Pinto, P., Poage, W., Raj, G. V., Rebbeck, T. R., Ryan, C., Sandler, H., Schiewer, M., Scott, E. M. D., Szymaniak, B., Tester, W., Trabulsi, E. J., Vapiwala, N., Yu, E. Y., Zeigler-Johnson, C., & Gomella, L. G.
- Venue
- Journal of Clinical Oncology
- Published
- 2020-08-20
- Volume
- 38
- Issue
- 24
- Pages
- 2798-2811
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W3033920919
- Cited by
- 275
- References
- 76
- FWCI
- 23.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.